The transaction represents Laboratorios Saval’s entry into the pharmaceutical market in Costa Rica through the acquisition of Stein’s production plant in Cartago. The facilities cover approximately 9,000 m², with the capacity to manufacture solid products (tablets, and capsules, among others) and liquids (syrups). 

BLP advised Saval throughout the acquisition process of Laboratorios Stein’s operations in Costa Rica, including the execution of the due diligence process, the structuring of the transaction, the negotiation of the purchase agreement and ancillary contracts, as well as in the entry of Saval to the Costa Rican market through the obtention of the applicable permits and the hiring of 170 employees. 

SAVAL’s acquisition will allow the launch of more than 20 products related to neuroscience, cardiology, and ophthalmology, contributing to the health of patients and clients in the region, by offering a wide range of accessible and quality products. This acquisition responds to SAVAL’s 2030 Strategic Plan to increase its international positioning.  

Leading the BLP team in this transaction were partners Adelina Villalobos and Ronald Lachner, and director Elia Naranjo, with the support of attorneys Alexandra Aguilar, Andrea Sittenfeld, Anneth Jiménez, Diego Quirós, Fiorella Chinchilla, Giselle Reuben, Ignacio Alonso, León Weinstok, Luis Hernández, Luis Ortiz, Luis Palacios, Madeleine Garrón, Tatiana Chacón, Tatiana Hernández, Vittoria Di Gioacchino and Yannsi Paniagua.